Results 121 to 130 of about 37,814 (299)

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Biomedical Papers, 2015
Aims: The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database.
Oldrich Chrapek, Jiri Jarkovsky, Jan Studnicka, Martin Sin, Petr Kolar, Barbora Jirkova, Ladislav Dusek, Sarka Pitrova, Jiri Rehak   +8 more
doaj   +1 more source

Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.

JAMA ophthalmology, 2020
Importance Preservation of peripheral visual field (VF) is considered an advantage for anti-vascular endothelial growth factor agents compared with panretinal photocoagulation (PRP) for treatment of proliferative diabetic retinopathy.
M. Maguire, Danni Liu, A. Glassman, L. Jampol, Chris A. Johnson, C. Baker, N. Bressler, T. Gardner, D. Pieramici, Cynthia R. Stockdale, Jennifer K. Sun   +10 more
semanticscholar   +1 more source

Impact of cataract surgery on patients receiving intravitreal therapy for retinal vein occlusion

Clinical &Experimental Ophthalmology, Volume 53, Issue 4, Page 374-383, May/June 2025.
Abstract Background To assess clinical outcomes of cataract surgery in eyes treated with intravitreal injections for cystoid macular oedema (CMO) secondary to retinal vein occlusions (RVOs). Methods Eyes receiving intravitreal injections for CMO secondary to RVOs that underwent cataract extraction were identified from the Fight Retinal Blindness ...
Alessandro Invernizzi, Matteo Airaldi, Mariano Cozzi, Vuong Nguyen, Yohei Hashimoto, Daniel Barthelmes, Louise O'Toole, Theodorus Leonardus Ponsioen, Pavol Kusenda, Francisco Javier Lavid, Nandor Jaross, Mark Gillies, Adrian Hunt   +12 more
wiley   +1 more source

Outliers of Treatment Frequency in Retinal Vein Occlusion: 24‐Month Comparative Analysis of Fight Retinal Blindness! Practitioners

Clinical &Experimental Ophthalmology, Volume 53, Issue 4, Page 409-420, May/June 2025.
ABSTRACT Background We aimed to describe a 2‐year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).
Theodorus Ponsioen, Yohei Hashimoto, Alessandro Invernizzi, Pierre‐Henry Gabrielle, Francisco Javier Lavid, Hemal Mehta, Rufino Silva, Nandor Jaross, David Squirrell, Louise O'Toole, Pavol Kusenda, Daniel Barthelmes, Mark Gillies, Adrian Hunt   +13 more
wiley   +1 more source

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

ClinicoEconomics and Outcomes Research, 2015
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Régnier SA, Malcolm W, Haig J, Xue W   +3 more
doaj  

Diabetic papillopathy treated with intravitreal ranibizumab

International Medical Case Reports Journal, 2017
In this report, we present a case of diabetic papillopathy that resolved after a single dose of intravitreal ranibizumab injection. A 50-year-old male presented with painless visual loss in his right eye. His visual acuity was 1/10 in the right eye and 10/10 in the left eye. Anterior segment examination of both eyes was unremarkable.
Deniz Kilic, Mehmet Dursun, Birgül Dursun, Mine Yildirim   +3 more
openaire   +5 more sources

StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR):Study protocol for a randomized controlled clinical trial [PDF]

, 2016
BACKGROUND: The standard of care for neovascular age-related macular degeneration (nAMD) involves ongoing intravitreal injections of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF).
Chakravarthy, Usha, Desai, Riti, Jackson, Timothy L, Kelly, Joanna, Lewis, Cornelius, Murphy, Caroline, Neffendorf, James E, O'Sullivan, Joe, Peacock, Janet, Reeves, Barnaby, Uddin, Shahir, Wang, Yanzhong, Wordsworth , S   +12 more
core   +2 more sources

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years

Al-Azhar Assiut Medical Journal, 2019
Background Diabetic macular edema (DME) is a common cause of blindness and visual impairment in diabetic patients, which can affect the quality of life.
Abd El-Magid M Tag El-Din
doaj   +1 more source

Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial

Translational Vision Science & Technology, 2020
Purpose To develop a population pharmacokinetic (PK) model for intravitreal ranibizumab in infants with retinopathy of prematurity (ROP) and assess plasma free vascular endothelial growth factor (VEGF) pharmacodynamics (PD).
M. Fidler, B. Fleck, A. Stahl, N. Marlow, J. Chastain, Jun Li, D. Lepore, J. Reynolds, M. Chiang, A. Fielder   +9 more
semanticscholar   +1 more source

Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases [PDF]

, 2016
published_or_final_versio
Behar-Cohen, F, De Falco, S, Lam, WC, Li, WW, Li, X, Nguyen, QD, Pluim, J, Reichhart, N, Ricci, F   +8 more
core   +1 more source